Anticancer Applications of Gold Complexes: Structure–Activity Review
Source abstract
Abstract
Background: Gold (Au) complexes have emerged as promising anticancer candidates due to their distinct coordination chemistry and ability to modulate thiol-dependent and redox-regulated cellular pathways, particularly thioredoxin reductase (TrxR). In recent years, structurally diverse Au(I) and Au(III) complexes have been reported with potent in vitro anticancer activity; however, cross-study comparability and design principles remain unclear. Aim: This systematic review critically evaluates anticancer Au(I/III) complexes reported since 2016, with the specific aim of identifying how oxidation state, coordination geometry, and ligand class influence in vitro potency, selectivity, and translational potential. Methods: A PRISMA-guided literature search was performed in Scopus, Web of Science, PubMed, and ScienceDirect for studies published between January 2016 and March 2025. Two independent reviewers screened titles/abstracts and full texts according to predefined inclusion criteria. Only original studies reporting anticancer activity of structurally characterized Au(I/III) complexes in human cancer models were included. After the removal of duplicates, 1100 records were screened at the title and abstract level. Of these, 240 articles were assessed in full text for eligibility. Ultimately, 128 studies reporting anticancer activity of structurally characterized Au(I/III) complexes met the inclusion criteria and were included in the qualitative synthesis. Biological potency data were harmonized to μM units where applicable, and results were synthesized qualitatively due to heterogeneity in experimental design. Results: A total of 128 studies met the inclusion criteria. Au(I) complexes—particularly phosphine- and N-heterocyclic carbene (NHC)-based compounds—consistently showed sub-micromolar cytotoxicity in TrxR-dependent cancer cell lines, whereas Au(III) complexes displayed greater structural diversity but variable stability and redox behavior. In vivo efficacy was reported for a limited subset of compounds and was frequently constrained by solubility, systemic toxicity, or metabolic instability. Conclusions: The available evidence indicates that anticancer activity of gold complexes is strongly dependent on oxidation state, ligand environment, and redox stability. While Au(I) scaffolds show more reproducible in vitro potency, successful translation to in vivo models remains limited. This review defines structure–activity and structure–liability relationships that can guide the rational design of next-generation gold-based anticancer agents.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Metal complexes synthesis and properties · Ferrocene Chemistry and Applications · Redox biology and oxidative stress
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of General and Inorganic Chemistry with Methodology of Chemistry Education, Faculty of Chemistry, University of Plovdiv, “Tzar Assen” Str. 24, 4000 Plovdiv, Bulgaria
Department of Microbiology and Biotechnology, University of Food Technologies, 26 Maritza Blvd., 4002 Plovdiv, Bulgaria
Department of Organic Chemistry, Faculty of Chemistry, University of Plovdiv, 4000 Plovdiv, Bulgaria
Funding
Scientific Research of the Plovdiv University · European Union—Next Generation EU, through the National Recovery and Resilience Plan of the Republic of Bulgaria
References (100+)
Show source-provided references
1. Transforming the landscape of cancer treatment with seven promising novel therapies: Evolution and future perspectives10.1016/j.medp.2025.100087 ↗
2. Advancements and limitations in traditional anti-cancer therapies: A comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy10.1007/s12672-025-02198-8 ↗
3. Murillo, M.I., Gaiddon, C., and Le Lagadec, R. (2022). Targeting of the intracellular redox balance by metal complexes towards anticancer therapy. Front. Chem., 10.10.3389/fchem.2022.967337 ↗
4. Metal complexes in cancer therapy—An update from drug design perspective10.2147/DDDT.S119488 ↗
5. Novel metals and metal complexes as platforms for cancer therapy10.2174/138161210791209009 ↗
6. Stefanache, A., Miftode, A.M., Constantin, M., Bogdan Goroftei, R.E., Olaru, I., Gutu, C., Vornicu, A., and Lungu, I.I. (2025). Noble Metal Complexes in Cancer Therapy: Unlocking Redox Potential for Next-Gen Treatments. Inorganics, 13.10.3390/inorganics13020064 ↗
7. Various Methods of Synthesis and Applications of Gold-Based Nanomaterials: A Detailed Review10.1021/acs.cgd.4c01687 ↗
8. Pasha, S.K.K., Deshmukh, K., and Hussain, C.M. (2025). Surface Chemistry and Physiological Characteristics of Gold Nanoparticles. Gold Nanoparticles, Nanomaterials and Nanocomposites, Elsevier.
9. Main Avenues in Gold Coordination Chemistry10.1021/acs.chemrev.0c00930 ↗
10. Functional utility of gold complexes with phosphorus donor ligands in biological systems10.1016/j.ccr.2024.216208 ↗
11. Complexation of Gold(I) and Gold(III) in solutions10.1016/j.ccr.2024.216162 ↗
12. Radisavljević, S., and Petrović, B. (2020). Gold(III) Complexes: An Overview on Their Kinetics, Interactions With DNA/BSA, Cytotoxic Activity, and Computational Calculations. Front. Chem., 8.10.3389/fchem.2020.00379 ↗
13. A multitarget gold(I) complex induces cytotoxicity related to aneuploidy in HCT-116 colorectal carcinoma cells10.1002/anie.202006212 ↗
14. Water-soluble gold(III)-metformin complex alters mitochondrial bioenergetics in breast cancer cells10.1002/cmdc.202100233 ↗
15. Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer10.1097/CAD.0000000000000009 ↗
16. The gold complex auranofin: New perspectives for cancer therapy10.1007/s12672-021-00439-0 ↗
17. Mitochondria as a target of third row transition metal-based anticancer complexes10.1016/j.cbpa.2022.102235 ↗
18. On the potential of thioredoxin reductase inhibitors for cancer therapy10.1016/j.semcancer.2006.09.004 ↗
19. Seitz, R., Tümen, D., Kunst, C., Heumann, P., Schmid, S., Kandulski, A., Müller, M., and Gülow, K. (2024). Exploring the Thioredoxin System as a Therapeutic Target in Cancer: Mechanisms and Implications. Antioxidants, 13.10.3390/antiox13091078 ↗
20. Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma10.1016/j.redox.2019.101310 ↗
21. Yeo, C.I., Ooi, K.K., and Tiekink, E.R.T. (2018). Gold-Based Medicine: A Paradigm Shift in Anti-Cancer Therapy?. Molecules, 23.10.3390/molecules23061410 ↗
22. Marinova, P., Stoitsov, D., Burdzhiev, N., Tsoneva, S., Blazheva, D., Slavchev, A., Varbanova, E., and Penchev, P. (2024). Investigation of the Complexation Activity of 2,4-Dithiouracil with Au(III) and Cu(II) and Biological Activity of the Newly Formed Complexes. Appl. Sci., 14.10.3390/app14156601 ↗
23. Ratia, C., Ballén, V., Gabasa, Y., Soengas, R.G., Andrés, M.V.-D., Iglesias, M.J., Cheng, Q., Lozano, F., Arnér, E.S.J., and López-Ortiz, F. (2023). Novel gold(III)-dithiocarbamate complex targeting bacterial thioredoxin reductase: Antimicrobial activity, synergy, toxicity, and mechanistic insights. Front. Microbiol., 14.10.3389/fmicb.2023.1198473 ↗
24. Anticancer Activity of Alkynylgold(I) with P(NMe2)3 Phosphane in Mouse Colon Tumors and Human Colon Carcinoma Caco-2 Cell Line10.1021/acs.inorgchem.9b02528 ↗
25. Thioredoxin reductase selenoproteins from different organisms as potential drug targets for treatment of human diseases10.1016/j.freeradbiomed.2022.07.020 ↗
26. Kou, L., Wei, S., and Kou, P. (2021). Current Progress and Perspectives on Using Gold Compounds for the Modulation of Tumor Cell Metabolism. Front. Chem., 9.10.3389/fchem.2021.733463 ↗
27. Gold(I) and gold(III) N-heterocyclic carbene complexes as antibacterial agents and inhibitors of bacterial thioredoxin reductase10.1002/cmdc.202100381 ↗
28. Gold Nanoclusters as Nanoantibiotic Auranofin Analogues10.1002/adhm.202101032 ↗
29. Thioredoxin (Trx): A redox target and modulator of cellular senescence and aging-related diseases10.1016/j.redox.2024.103032 ↗
30. Jovanović, M., Podolski-Renić, A., Krasavin, M., and Pešić, M. (2022). The Role of the Thioredoxin Detoxification System in Cancer Progression and Resistance. Front. Mol. Biosci., 9.10.3389/fmolb.2022.883297 ↗
31. Significance of the mitochondrial thioredoxin reductase in cancer cells: An update on role, targets and inhibitors10.1016/j.freeradbiomed.2018.03.043 ↗
32. Brandl, N., Seitz, R., Sendtner, N., Müller, M., and Gülow, K. (2025). Living on the Edge: ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target. Antioxidants, 14.10.3390/antiox14081002 ↗
33. Dos Santos, Reactivity of auranofin with S-, Se- and N-containing amino acids10.1016/j.comptc.2014.09.005 ↗
34. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo10.1038/cddis.2014.132 ↗
35. Salmain, M., Gaschard, M., Baroud, M., Lepeltier, E., Jaouen, G., Passirani, C., and Vessières, A. (2023). Thioredoxin Reductase and Organometallic Complexes: A Pivotal System to Tackle Multidrug Resistant Tumors?. Cancers, 15.10.3390/cancers15184448 ↗
36. Selective inhibition of endogenous antioxidants with Auranofin causes mitochondrial oxidative stress which can be countered by selenium supplementation10.1016/j.bcp.2017.09.009 ↗
37. Exploring the Anticancer Activity of Tamoxifen-Based Metal Complexes Targeting Mitochondria10.1021/acs.jmedchem.3c00617 ↗
38. A Review on Metal Complexes and Its Anti-Cancer Activities: Recent Updates from In Vivo Studies10.1016/j.biopha.2024.116211 ↗
39. Tialiou, A., Chin, J., Keppler, B.K., and Reithofer, M.R. (2022). Current Developments of N-Heterocyclic Carbene Au(I)/Au(III) Complexes toward Cancer Treatment. Biomedicines, 10.10.3390/biomedicines10061417 ↗
40. Tolbatov, I., Marrone, A., Coletti, C., and Re, N. (2021). Computational Studies of Au(I) and Au(III) Anticancer MetalLodrugs: A Survey. Molecules, 26.10.3390/molecules26247600 ↗
41. Promising heterometallic compounds as anticancer agents: Recent studies in vivo
42. Gold Complexes in Anticancer Therapy: From New Design Principles to Particle-Based Delivery Systems10.1002/anie.202218000 ↗
43. Sourav De, Organorhenium complexes as theranostic agents: Bridging anticancer activity and molecular sensing
44. Gold(I) complexes of the type [AuL{κC-2-C6H4P(S)Ph2}] [L = PTA, PPh3, PPh2(C6H4-3-SO3Na) and PPh2(2-py)]: Synthesis, characterisation, crystal structures, and In Vitro and In Vivo anticancer properties10.1016/j.ejmech.2024.117007 ↗
45. Gold-based therapy: From past to present10.1073/pnas.2007285117 ↗
46. Recent development of gold(I) and gold(III) complexes as therapeutic agents for cancer diseases10.1039/D1CS00933H ↗
47. Gold nanoparticles as a potent radiosensitizer: A transdisciplinary approach from physics to patient10.3390/cancers12082021 ↗
48. Gold–NHC complexes: From synthetic aspects to anti-cancer activity10.1039/D5DT00118H ↗
49. Exploring the catalytic and anticancer activity of gold(I) complexes bearing 1,3,5-triaza-7-phosphaadamantane (PTA) and related ligands10.1039/D5NJ01194A ↗
50. Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models
51. Synthesis and evaluation of doxorubicin-loaded gold nanoparticles for tumor-targeted drug delivery10.1021/acs.bioconjchem.7b00756 ↗
52. Modeling the metabolic response of A2780 ovarian cancer cells to gold-based cytotoxic drugs10.1038/s41540-025-00535-9 ↗
53. Ghini, V., Sorbi, F., Fambrini, M., and Magherini, F. (2024). NMR Metabolomics of Primary Ovarian Cancer Cells in Comparison to Established Cisplatin-Resistant and -Sensitive Cell Lines. Cells, 13.10.3390/cells13080661 ↗
54. MCF-7 cells--changing the course of breast cancer research and care for 45 years10.1093/jnci/djv073 ↗
55. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research
56. Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells10.1016/j.tiv.2005.03.006 ↗
57. Recent approaches of toxicity-related attributes of NMs: A systematic review10.1016/j.nwnano.2025.100160 ↗
58. Köllő, Z., Garami, M., Vincze, I., Vásárhelyi, B., and Karvaly, G.B. (2023). Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces-A Review. Pharmaceutics, 15.10.3390/pharmaceutics15010239 ↗
59. Singhal, S.S., Garg, R., Mohanty, A., Garg, P., Ramisetty, S.K., Mirzapoiazova, T., Soldi, R., Sharma, S., Kulkarni, P., and Salgia, R. (2023). Recent Advancement in Breast Cancer Research: Insights from Model Organisms—Mouse Models to Zebrafish. Cancers, 15.10.3390/cancers15112961 ↗
60. Anticancer Agents: Does a Phosphonium Behave Like a Gold(I) Phosphine Complex? Let a “Smart” Probe Answer!10.1021/acs.jmedchem.5b00480 ↗
61. Quero, J., Ruighi, F., Osada, J., Gimeno, M.C., Cerrada, E., and Rodriguez-Yoldi, M.J. (2021). Gold(I) Complexes Bearing Alkylated 1,3,5-Triaza-7-phosphaadamantane Ligands as Thermoresponsive Anticancer Agents in Human Colon Cells. Biomedicines, 9.10.3390/biomedicines9121848 ↗
62. Homobimetallic Au(I)–Au(I) and Heterotrimetallic Au(I)–Fe(II)–Au(I) Complexes with Dialkyldithiophosphates and Phosphine Ligands: Structural Characterization, DFT Analysis, and Tyrosinase Inhibitory and Biological Effects10.1021/acsomega.3c00645 ↗
63. Phosphine Functionalized CpC Ligands and Their Metal Complexes10.3390/chemistry5020062 ↗
64. Mihajlović, L.E., Trif, M., and Živković, M.B. (2025). Metal Complexes with Hydroxyflavones: A Study of Anticancer and Antimicrobial Activities. Inorganics, 13.10.3390/inorganics13080250 ↗
65. The leaving group in Au(I)-phosphine compounds dictates cytotoxic pathways in CEM leukemia cells and reactivity towards a Cys2His2 model zinc finger10.1039/D0DT01136C ↗
66. Advancing cancer therapy: The role of silver(I) phosphine complexes in overcoming resistance and toxicity10.1007/s12672-025-02657-2 ↗
67. Pirvu, A.S., Varut, R.-M., Trasca, D.-M., Stoica, G.A., Radivojevic, K., Carmen, S., Arsenie, C.C., and Popescu, C. (2025). Cyclodextrins as Active Therapeutic Agents: Beyond Their Role as Excipients. Pharmaceuticals, 18.10.3390/ph18101592 ↗
68. Advances in targeted therapy for tumor with nanocarriers: A review10.1016/j.mtbio.2025.101583 ↗
69. Astolfi, P., Pisani, M., Giorgini, E., Rossi, B., Damin, A., Vita, F., Francescangeli, O., Luciani, L., and Galassi, R. (2020). Synchrotron characterization of hexagonal and cubic lipidic phases loaded with azolate/phosphane gold(I) compounds: A new approach to the uploading of gold(I)-based drugs. Nanomaterials, 10.10.3390/nano10091851 ↗
70. In vitro and in vivo studies of gold(I) azolate/phosphane complexes for the treatment of basal like breast cancer10.1016/j.ejmech.2018.06.002 ↗
71. Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives10.1016/j.ejmech.2015.11.003 ↗
72. Comparative studies on the cytotoxicity, cellular and nuclear uptake of a series of chloro gold(I) phosphine complexes10.1016/j.poly.2009.06.007 ↗
73. Synthesis of Gold(I) Complexes Containing Cinnamide: In Vitro Evaluation of Anticancer Activity in 2D and 3D Spheroidal Models of Melanoma and In Vivo Angiogenesis10.1021/acs.inorgchem.9b00281 ↗
74. Gold(I/III)-Phosphine Complexes as Potent Antiproliferative Agents10.1038/s41598-019-48584-5 ↗
75. Carbon-phosphorus stapled Au(I) anticancer agents via bisphosphine induced reductive elimination10.1039/D4DT01929F ↗
76. Sadler, P.J., and van Eldik, R. (2020). Metal N-heterocyclic carbene complexes in medicinal chemistry. Advances in Inorganic Chemistry, Academic Press.
77. N-Heterocyclic Carbenes as Ligands to 198Au(I)-Radiolabeled Compounds: A New Platform for Radiopharmaceutical Design10.1021/acs.jmedchem.5c01073 ↗
78. Tolbatov, I., Umari, P., and Marrone, A. (2024). Mechanism of Action of Antitumor Au(I) N-Heterocyclic Carbene Complexes: A Computational Insight on the Targeting of TrxR Selenocysteine. Int. J. Mol. Sci., 25.10.3390/ijms25052625 ↗
79. The divergent effects of strong NHC donation in catalysis10.1039/C5SC02592C ↗
80. Akkattu, T., and Biju, A.T. (2019). An Overview of NHCs. N-Heterocyclic Carbenes in Organocatalysis, Wiley-VCH Verlag GmbH & Co. KgaA. [1st ed.].
81. Cationic, linear Au(I) N-heterocyclic carbene complexes: Synthesis, structure and anti-mitochondrial activity10.1039/b602560a ↗
82. Curran, D., Müller-Bunz, H., Bär, S.I., Schobert, R., Zhu, X., and Tacke, M. (2020). Novel Anticancer NHC*-Gold(I) Complexes Inspired by Lepidiline A. Molecules, 25.10.3390/molecules25153474 ↗
83. Ceramella, J., Mariconda, A., Sirignano, M., Iacopetta, D., Rosano, C., Catalano, A., Saturnino, C., Sinicropi, M.S., and Longo, P. (2022). Novel Au Carbene Complexes as Promising Multi-Target Agents in Breast Cancer Treatment. Pharmaceuticals, 15.10.3390/ph15050507 ↗
84. Synthesis and structural characterisation of linear Au(I) N-heterocyclic carbene complexes: New analogues of the Au(I) phosphine drug Auranofin10.1016/j.jorganchem.2005.07.013 ↗
85. Font, P., Tzouras, N.V., Papastavrou, A.T., Vougioukalakis, G.C., and Ribas, X. (2023). Novel NHC-Based Au(I) Complexes as Precursors of Highly Pure Au(0) Nuggets under Oxidative Conditions. Molecules, 28.10.3390/molecules28052302 ↗
86. Update on metal N-heterocyclic carbene complexes as potential anti-tumor metallodrugs10.1016/j.ccr.2016.09.004 ↗
87. Halo and Pseudohalo Gold(I)–NHC Complexes Derived from 4,5-Diarylimidazoles with Excellent In Vitro and In Vivo Anticancer Activities Against HCC10.1021/acs.jmedchem.0c00257 ↗
88. In-vitro and in-vivo investigations into the carbene-gold anticancer drug candidates NHC*-Au-SCSNMe2 and NHC*-Au-S-GLUC against advanced prostate cancer PC310.1097/CAD.0000000000000930 ↗
89. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents10.2174/138945012803530224 ↗
90. Chmelyuk, N., Kordyukova, M., Sorokina, M., Sinyavskiy, S., Meshcheryakova, V., Belousov, V., and Abakumova, T. (2025). Inhibition of Thioredoxin-Reductase by Auranofin as a Pro-Oxidant Anticancer Strategy for Glioblastoma: In Vitro and In Vivo Studies. Int. J. Mol. Sci., 26.10.3390/ijms26052084 ↗
91. Selective cytotoxic activity of new lipophilic hydroxytyrosol alkyl ether derivatives10.1021/jf400796p ↗
92. Smart N-Heterocyclic Carbene Ligands in Catalysis10.1021/acs.chemrev.6b00695 ↗
93. Au NHC Complexes as Anticancer Agents: Milestones, Strategies and Future Developments10.1039/D5CS00924C ↗
94. N-Heterocyclic Carbene Complexes of Silver and Gold as Novel Tools Against Breast Cancer Progression10.4155/fmc-2016-0160 ↗
95. An organometallic approach to sub-2 nm thiolate-protected Au nanoclusters with enhanced catalytic and therapeutic properties10.1039/D5NA00123D ↗
96. Dual Catalysis of Gold Nanoclusters: Photocatalytic Cross-Dehydrogenative Coupling by Cooperation of Superatomic Core and Molecularly Modified Staples10.1002/anie.202312135 ↗
97. Alkynyl Approach toward the Protection of Metal Nanoclusters10.1021/acs.accounts.8b00359 ↗
98. Understanding the Ligand-Dependent Photoluminescent Mechanism in Small Alkynyl-Protected Gold Nanoclusters10.1021/acs.jpca.3c04644 ↗
99. Revealing the exchange kinetics of thiol-capped Au25 nanoclusters with alkynyl ligands10.1039/D5SC04701C ↗
100. Alkynyl-protected gold and gold-silver nanoclusters10.1039/C6DT04763G ↗